Nature Biotechnology 24, 230 - 231 (2006)
Published online: 6 March 2006; | doi:10.1038/nbt0306-230
Toll-like receptor therapies compete to reduce side effectsCharlie Schmidt
Portland, Maine
An emerging class of highly specific immunomodulator drugs targeting toll-like receptors will be the focus of attention this month at a conference in Salvador, Brazil.
|
